These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34903958)

  • 21. Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives.
    Meliante PG; Petrella C; Fiore M; Minni A; Barbato C
    Curr Issues Mol Biol; 2023 Nov; 45(11):9215-9233. PubMed ID: 37998754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune alterations and immunotherapy prospects in head and neck cancer.
    Varilla V; Atienza J; Dasanu CA
    Expert Opin Biol Ther; 2013 Sep; 13(9):1241-56. PubMed ID: 23789839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.
    Schutt CA; Mirandola L; Figueroa JA; Nguyen DD; Cordero J; Bumm K; Judson BL; Chiriva-Internati M
    Oncotarget; 2017 Nov; 8(59):100280-100287. PubMed ID: 29245977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
    Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
    J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Su YY; Chien CY; Luo SD; Huang TL; Lin WC; Fang FM; Chiu TJ; Chen YH; Lai CC; Hsu CM; Li SH
    World J Surg Oncol; 2016 Mar; 14():86. PubMed ID: 27001663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miRNAs in head and neck cancer revisited.
    Nagadia R; Pandit P; Coman WB; Cooper-White J; Punyadeera C
    Cell Oncol (Dordr); 2013 Feb; 36(1):1-7. PubMed ID: 23338821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population.
    Maruyama H; Yasui T; Ishikawa-Fujiwara T; Morii E; Yamamoto Y; Yoshii T; Takenaka Y; Nakahara S; Todo T; Hongyo T; Inohara H
    Cancer Sci; 2014 Apr; 105(4):409-17. PubMed ID: 24521534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy.
    Damasio MPS; Nascimento CS; Andrade LM; de Oliveira VL; Calzavara-Silva CE
    Front Oncol; 2022; 12():1021609. PubMed ID: 36338731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoscopic screening for synchronous esophageal neoplasia among patients with incident head and neck cancer: Prevalence, risk factors, and outcomes.
    Wang YK; Chuang YS; Wu TS; Lee KW; Wu CW; Wang HC; Kuo CT; Lee CH; Kuo WR; Chen CH; Wu DC; Wu IC
    Int J Cancer; 2017 Nov; 141(10):1987-1996. PubMed ID: 28758200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma.
    Yu C; Li Q; Zhang Y; Wen ZF; Dong H; Mou Y
    Front Cell Dev Biol; 2022; 10():941750. PubMed ID: 36092724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular landscape of head and neck cancer and implications for therapy.
    Farah CS
    Ann Transl Med; 2021 May; 9(10):915. PubMed ID: 34164549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma.
    Wondergem NE; Nijenhuis DNLM; Poell JB; Leemans CR; Brakenhoff RH; van de Ven R
    Front Oral Health; 2021; 2():647980. PubMed ID: 35047999
    [No Abstract]   [Full Text] [Related]  

  • 35. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.
    Descamps G; Karaca Y; Lechien JR; Kindt N; Decaestecker C; Remmelink M; Larsimont D; Andry G; Hassid S; Rodriguez A; Khalife M; Journe F; Saussez S
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2185-96. PubMed ID: 27370781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma.
    Kokko LL; Hurme S; Maula SM; Alanen K; Grénman R; Kinnunen I; Ventelä S
    Oral Oncol; 2011 Jun; 47(6):510-6. PubMed ID: 21514878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapies for head and neck squamous cell carcinomas].
    Yan XJ; Xu KL; Zhang XX
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jul; 31(13):1050-1056. PubMed ID: 29798179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.
    Economopoulou P; Kotsantis I; Psyrri A
    ESMO Open; 2016; 1(6):e000122. PubMed ID: 28848660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy.
    Canning M; Guo G; Yu M; Myint C; Groves MW; Byrd JK; Cui Y
    Front Cell Dev Biol; 2019; 7():52. PubMed ID: 31024913
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.